– Hypersensitivity to Cabergoline.
– Contraindicated in patients with hepatic insufficiency and with toxaemia of pregnancy.

Precaution & warning:
– Delcabrin should be given with caution to subjects with cardio- vascular disease

– Not recommended during pregnancy or during lactation

– Must be wary of a pregnancy after a month of stop taking the drug – The safety and efficacy of Delcabrin has not been established in subjects less than 16 years of age

– Store in temperature below 30 C.

strip contains 2 scored tablets


Each tablet contains: 0.5 mg Cabergoline

Properties and Indications

Delcabrin is indicated for the inhibition of physiological lactation soon after  delivery, after stillbirth or abortion and for ؤ suppression of already established lactation.
Treatment of hyperprolactinaemic disorders

For inhibition of lactation

Delcabrin should be administered during the first day post-partum. The recommended therapeutic dose is 1 mg (two 0.5 mg tablets) given as a single dose

For suppression of established lactation:

The recommended therapeutic dosage regimen is 0.25 mg (one-half 0.5 mg tablet) every 12 hours for two days (1 mg total dose).

Treatment of hyperprolactinaemic disorders

– The recommended initial dosage of Delcabrin is 0.5 mg per week given in one or two (one-half of one 0.5 mg tablet) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually, preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved.

– The therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week. Doses of Delcabrin up to 4.5 mg per week have been used in hyperprolactinaemic patients.

– The maximum dose should not exceed 3 mg per day